Analyst Reco. Orphazyme A/S

Equities

Delayed Nasdaq Copenhagen Other stock markets 09:37:19 2024-05-02 am EDT			5-day change	1st Jan Change
988.3 ^DKK	-8.81%		-9.69%	-25.69%

Mar. 27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

ORPHAZYME A/S : Guggenheim Downgrades Orphazyme to Sell From Neutral	21-06-21	MT
ORPHAZYME A/S : Cowen Downgrades Orphazyme A/S to Market Perform From Outperform	21-06-21	MT
ORPHAZYME A/S : BofA Securities Lowers Orphazyme A/S to Underperform From Neutral, Price Target to $5 From $13	21-03-30	MT

No results for this search